Request for Free Sample

Brachytherapy Market Size Analysis:

The Brachytherapy Market was valued at USD 949.86 million in 2023 and is expected to reach USD 1775.84 million by 2032, growing at a CAGR of 7.23% from 2024-2032.

This report provides insights into the Brachytherapy Market by presenting detailed statistical analyses not commonly included in regular market reports. It provides procedure volume and utilization rates broken down by region, providing a granular clinical adoption perspective. The report also discusses cancer incidence by type and evaluates the percentage of patients who can be treated with brachytherapy. Further, it also contains information about HDR and LDR equipment base installed over time and analyzes reimbursement systems in a geographic region from government, private, and out-of-pocket systems. These singular measurements allow the measurement of more effective market penetration, technology usage, and worldwide brachytherapy service availability.

The U.S. Brachytherapy Market was valued at USD 311.26 million in 2023 and is expected to reach USD 504.89 million by 2032, growing at a CAGR of 5.54% from 2024-2032. The United States has a commanding presence in the North American Brachytherapy Market because of its sophisticated oncology infrastructure, increased adoption of HDR and LDR systems, and strong emphasis on cancer screening and early treatment. Favorable payment policies and continuous investments in radiotherapy technologies also further establish the U.S.'s dominance in this regional market.

Brachytherapy Market Dynamics

Drivers

  • Rising Global Cancer Burden Boosting Demand for Localized Radiotherapy is driving the market growth.

The growing worldwide prevalence of cancers—specifically prostate, breast, cervical, and skin cancers—remains to propel interest in targeted and minimally invasive treatment approaches such as brachytherapy. GLOBOCAN 2023 estimates that there were 20 million new cancer diagnoses worldwide, and among the most prevalent were prostate and breast cancers. Brachytherapy delivers highly localized radiation with minimal harm to adjacent tissues, which is best suited to treating tumors in sensitive areas. For instance, high-dose rate (HDR) brachytherapy is increasingly being adopted in outpatient environments, enhancing patient comfort and minimizing hospital admissions. Recent technology developments, including real-time imaging guidance and advanced applicators, have improved procedural precision and results. In addition, the implementation of electronic brachytherapy systems, such as Elekta's Esteya and Varian's VariSource iX, is embracing the movement toward personalized, efficient, and organ-sparing cancer treatment.

  • Advancements in brachytherapy delivery systems and cooperation between major players are driving market growth considerably.

Advances in treatment planning software, real-time dosimetry, and robotic delivery are enhancing procedural efficacy and treatment results. One prime example is the October 2023 acquisition by Elekta of iCAD Inc.'s Xoft Electronic Brachytherapy (eBx) System, enabling it to strengthen its product line for breast and gynecologic cancers. In the same way, the September 2024 partnership between Varian (a Siemens Healthineers company) and Sun Nuclear will see radiotherapy solutions combined with the SunCHECK quality assurance platform. These innovations guarantee accurate dosing, reduce side effects, and shorten treatment times, thus driving clinical acceptance higher. The incorporation of AI within brachytherapy planning and patient surveillance further enhances its attractiveness, particularly in countries making the transition from older external beam radiotherapies to more sophisticated, individualized treatments.                                        

Restraint

  • Limited Availability of Skilled Professionals and Infrastructure is restraining the market growth.

One of the most significant restrictions preventing the brachytherapy market from expanding is the limited number of qualified radiation oncologists, medical physicists, and technicians necessary to conduct accurate brachytherapy treatments. Unlike traditional radiotherapy, brachytherapy is a complex planning process, the precise insertion of radioactive sources and strict safety measures that necessitate high standards of expertise. Most hospitals, particularly in low- and middle-income nations, are not equipped with the infrastructure needed, including HDR afterloaders and real-time imaging systems, further limiting access to this innovative treatment. The International Atomic Energy Agency (IAEA) in a 2023 report identified that more than 70% of low-income countries have no specialized brachytherapy units. This shortage generates large treatment gaps and restricts patient access to effective localized cancer therapy, even though the established clinical benefits of brachytherapy in terms of precision, effectiveness, and lower side effects are well known.

Opportunities

  • Expansion of Brachytherapy Applications Beyond Oncology is creating a significant opportunity for the brachytherapy market.

Though brachytherapy has conventionally been applied in the management of cancers like prostate, cervical, and breast, new research is increasingly looking at its potential to treat non-oncological conditions like cardiac arrhythmias and keloid scars. This expansion of the application area presents a big market opportunity because it provides access to new patient pools and therapeutic areas. Besides, improvements in electronic and image-guided brachytherapy systems are also rendering treatments more targeted, hence improving safety and results. Organizations such as the FDA have also recently approved electronic brachytherapy equipment for the treatment of superficial skin cancers and non-melanoma indications, broadening application scenarios. As minimally invasive treatments become increasingly acceptable, medical professionals are more open to embracing brachytherapy for uses other than conventional cancer treatment, offering promising growth opportunities for manufacturers and developers of these products.

Challenges

  • High Initial Investment and Maintenance Costs are challenging the market from growing.

Even with its clinical advantages, brachytherapy is still a capital-draining form of treatment. Setting it up takes a heavy outlay of investment in equipment like afterloading machines, high-end imaging technology, and radiation shielding. Furthermore, ongoing costs associated with maintenance, calibration, and regulatory compliance place an additional economic burden on health facilities. Small- to mid-scale hospitals, especially in developing economies, often face economic constraints to set up or maintain brachytherapy departments. As of 2023, more than 60% of cancer centers across low-resource countries report that fiscal limitations are the major obstacle against adopting brachytherapy service, an argument cited in many such institutions as a result. The limitation presents not just limitations in the global expansion of the treatment but also exaggerates disparities within access to effective care, mainly in areas with increasing cancer burdens and few expenditures on healthcare.

Brachytherapy Market Segmentation Analysis

By Dosage

In 2023, the High-Dose Rate (HDR) brachytherapy segment dominated the brachytherapy market with a market share of 73.40%. This dominance is due to its high treatment efficacy, which enables high doses of radiation to be administered in shorter time frames, frequently in outpatient facilities. This reduces hospital stays and improves patient convenience. Moreover, HDR brachytherapy provides great accuracy, delivering the radiation dose directly to tumors while sparing nearby healthy tissues, thereby minimizing side effects and enhancing treatment safety. Its ability to treat a broad spectrum of cancers, such as prostate, cervical, and breast cancers, also adds to its clinical utility. The provided demand for precise, time-saving, and affordable cancer treatments has made HDR brachytherapy a first-choice treatment among medical practitioners, playing a vital role in its extensive use and dominance in the international market of brachytherapy.

By Product

In 2023, the Applicators & Afterloaders segment dominated the brachytherapy market with a 45.20% market share. This is largely attributed to their critical role of providing targeted, accurate radiation to cancerous tissue while reducing exposure to healthy surrounding cells. Applicators are crucial in positioning radioactive sources close to or inside the tumor, providing minimally invasive treatments that improve patient comfort and shorten recovery times. In the meantime, afterloaders facilitate precise placement and coordination of radiation administration with high-dose-rate (HDR) brachytherapy, enhancing the safety and effectiveness of treatment. Advances in technology, including Elekta's introduction of the Geneva universal gynecological brachytherapy applicator, have enhanced the versatility of treatment and superior clinical outcomes. These advances, coupled with the growing clinical desire for precision therapies, have gone a long way in endowing the segment with market dominance.

By Application

The prostate cancer segment dominated the brachytherapy market with 33.15% market share. This is primarily because brachytherapy has proven to be effective for treating localized prostate cancer, providing targeted radiation delivery that reduces exposure to adjacent healthy tissues. The procedure also comes with shorter treatment durations and faster patient recovery than other therapies. The growing incidence of prostate cancer worldwide has further fueled the demand for brachytherapy as a treatment choice. Additionally, positive reimbursement schemes in developed economies and ongoing evolution in imaging and planning technologies have further strengthened the dominance of the segment. Having well-established clinical guidelines has also helped in generating greater physician confidence in selecting brachytherapy for the management of prostate cancer.

The breast cancer segment is expected to show the fastest growth in the brachytherapy market in the forecast period, with 7.73% CAGR. This expected growth is due to the increasing prevalence of breast cancer globally and the increasing demand for minimally invasive treatments. Advances in technology, including the creation of High-Dose Rate (HDR) brachytherapy, have improved treatment accuracy and minimized side effects, so that brachytherapy has become a growingly feasible alternative for breast cancer patients. Additionally, greater awareness and early detection efforts have seen more breast cancers diagnosed at stages where brachytherapy works best, hence driving its usage. Increased research activities and the inclusion of brachytherapy in breast-conserving treatments have contributed further to this trend, particularly in countries with increasing oncology infrastructure.

Brachytherapy Market Regional Insights

North America dominated the Brachytherapy Market with a 46.60% market share in 2023 because of its established healthcare infrastructure, early adoption of innovative radiotherapy technologies, and high incidence of cancer cases, most notably prostate and breast cancers. The region is favored by huge government and private investments in cancer research and supportive reimbursement policies that enable access to brachytherapy treatments. Also, having key market participants, strategic purchase transactions, and intense clinical study activity are contributing to the domination of the area in terms of innovation and several various brachytherapy modalities like high-dose rate (HDR), low-dose rate (LDR), and electronic brachytherapy.

Asia Pacific is expected to be the fastest-growing Brachytherapy Market with 7.95% CAGR throughout the forecast period on account of a rising incidence of cancer, the growing healthcare infrastructure, and higher awareness regarding options in radiotherapy. China, India, and Japan are experiencing rapid growth of oncology centers and state-sponsored programs promoting increased accessibility for cancer treatment. In addition, increasing demand for affordable therapies, medical tourism on the rise, and expansion into emerging markets by global players are driving the penetration of brachytherapy in the region. With improved training and technical knowledge, the region is likely to play a critical role in driving the global growth trend of the treatment modality.

Brachytherapy Market Key Players

  • Elekta AB (Flexitron Afterloader, Esteya Electronic Brachytherapy System)

  • Varian Medical Systems, Inc. (GammaMedplus iX, VariSource iX)

  • Isoray Inc. (Cesium-131 (Cesium Blu), Blu Build Delivery System)

  • Becton, Dickinson and Company (BD) (TheraSeed Palladium-103, BrachySource Radioactive Seeds)

  • Eckert & Ziegler BEBIG (MultiSource HDR Afterloader, SagiNova HDR Afterloader)

  • CIVCO Radiotherapy (T-Guard Brachytherapy Shields, Universal Couchtop for Brachytherapy)

  • Boston Scientific Corporation (Xoft Axxent Electronic Brachytherapy System, Contura Multi-Lumen Balloon)

  • Theragenics Corporation (AgX100 Palladium-103, TheraSphere Y-90 Microspheres)

  • iCAD, Inc. (Xoft Axxent Brachytherapy, IORT Mobile Miniature X-ray System)

  • GT Medical Technologies (GammaTile Therapy, GT Medical Applicator)

  • Huiheng Medical, Inc. (HDR Afterloading Brachytherapy System, Brachytherapy Needle Applicators)

  • Panacea Medical Technologies Pvt. Ltd. (SIDDHANT HDR, SIDDHANT IORT)

  • Sensus Healthcare, Inc. (SRT-100 Vision, Sculptura IORT System)

  • Oncura, Inc. (OncoSeed I-125, ThinSeed I-125)

  • Nucletron B.V. (An Elekta Company) (Oncentra Brachy, MicroSelectron Digital)

  • C4 Imaging LLC (Sirius MRI Marker, C4 Seed Implant System)

  • Radiation Products Design, Inc. (Brachytherapy Needles, Source Train Kits)

  • BEBIG Medical GmbH (SagiPlan Treatment Planning System, SagiNova HDR Afterloader)

  • IsoAid LLC (Advantage I-125, Advantage Pd-103)

  • K&S Associates, Inc. (HDR Brachytherapy Phantoms, Brachytherapy Dosimetry Systems)

Suppliers (All these suppliers primarily provide radioisotopes (e.g., Iodine-125, Cesium-131, Palladium-103) and shielding materials or dosimetry systems that support safe and accurate delivery of brachytherapy treatments.) in the Brachytherapy Market

  • Medi-Physics, Inc.

  • Alpha Omega Services, Inc.

  • IBA Dosimetry GmbH

  • Nelco Worldwide

  • AmRay Radiation Protection

  • RadQual LLC

  • Eckert & Ziegler Isotope Products

  • QSA Global, Inc.

  • Ludlum Measurements, Inc.

  • Thermo Fisher Scientific Inc.

Recent Development in the Brachytherapy Market

  • October 2023 – Elekta agreed to acquire iCAD, Inc.'s Xoft business, including the Xoft Axxent Electronic Brachytherapy (eBx) System. This strategic deal allows Elekta to further its portfolio of cancer treatments by adding electronic brachytherapy technology for the treatment of indications like breast, non-melanoma skin, and gynecological cancers.

  • September 2024 – Siemens Healthineers company Varian formed a strategic partnership with Sun Nuclear to advance and broaden its quality assurance solutions. The partnership seeks to combine Sun Nuclear's SunCHECK quality management system with Varian's radiotherapy systems to provide improved quality assurance solutions in brachytherapy treatments.

  • December 2023 – Perspective Therapeutics, previously Isoray, announced the sale of its brachytherapy business—its radioactive Cesium-131 seed assets—to GT Medical Technologies. The transaction enables Perspective Therapeutics to concentrate on other therapeutic fields, while GT Medical further develops brachytherapy solutions.

    Brachytherapy Market Size, Share & Growth Report 2032
    Report Attributes Details
    Market Size in 2023 US$ 949.86 Million
    Market Size by 2032 US$ 1775.84 Million
    CAGR CAGR of 7.23 % From 2024 to 2032
    Base Year 2023
    Forecast Period 2024-2032
    Historical Data 2020-2022
    Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
    Key Segments • By Dosage (High-dose Rate (HDR) Brachytherapy, Low-dose Rate (LDR) Brachytherapy)
    • By Product (Seeds, Applicators & Afterloaders, Electronic Brachytherapy)
    • By Application (Prostate Cancer, Gynecological Cancer, Breast Cancer, Others)
    Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America)
    Company Profiles Elekta AB, Varian Medical Systems, Inc., Isoray Inc., Becton, Dickinson and Company (BD), Eckert & Ziegler BEBIG, CIVCO Radiotherapy, Boston Scientific Corporation, Theragenics Corporation, iCAD, Inc., GT Medical Technologies, Huiheng Medical, Inc., Panacea Medical Technologies Pvt. Ltd., Sensus Healthcare, Inc., Oncura, Inc., Nucletron B.V. (An Elekta Company), C4 Imaging LLC, Radiation Products Design, Inc., BEBIG Medical GmbH, IsoAid LLC, K&S Associates, Inc., and other players.